Ebola Vaccine for Children Becomes 81st U.S. FDA-Approval of BARDA-Supported Medical Countermeasure

BARDA reached its 81st regulatory approval, licensure, or clearance with the U.S. Food and Drug Administration (FDA) decision to expand the indication of Merck’s ERVEBO, a Zaire ebolavirus vaccine to prevent Ebolavirus disease (EVD) in pediatric patients aged 12 months and older.

Read the full press release from BARDA.